Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials Peter C. Taylor, MD, PhD, MA – University of Oxford
9:00 AM – 11:00 AM ET
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis Sylvain Mathieu – CHU Gabriel Montpied
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA Jonathan Kay, MD – University of Massachusetts Medical School
9:00 AM – 11:00 AM ET
Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy Zoltan Szekanecz, MD, PhD – University of Debrecen
9:00 AM – 11:00 AM ET
Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients Zoltan Szekanecz, MD, PhD – University of Debrecen
9:00 AM – 11:00 AM ET
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial DaeHyun Yoo, MD, PhD – Hanyang University Hospital for Rheumatic Diseases
9:00 AM – 11:00 AM ET
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial Rene Westhovens, MD, PhD – University Hospitals KU Leuven
9:00 AM – 11:00 AM ET
The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w Shuntaro Saito, MD, PhD, ARNP – Keio University School of Medicine
9:00 AM – 11:00 AM ET
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study Clifton O. Bingham, III, MD – Johns Hopkins University
9:00 AM – 11:00 AM ET
Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies Christina Charles-Schoeman, MD – UCLA Medical Center
9:00 AM – 11:00 AM ET
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA) Peter C. Taylor, MD, PhD, MA – University of Oxford
9:00 AM – 11:00 AM ET
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
9:00 AM – 11:00 AM ET
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies Grace C. Wright, MD, PhD – Grace C Wright MD PC
9:00 AM – 11:00 AM ET
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs David Walker, MD – Northumbria healthcare NHS Trust
9:00 AM – 11:00 AM ET
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study Rieke Alten, MD, PhD, Professor of Medicine – SCHLOSSPARK KLINIK, University Medicine Berlin
9:00 AM – 11:00 AM ET
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells Yuya Fujita, MD – Fukushima medical university
9:00 AM – 11:00 AM ET
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate Alan J. Kivitz, MD – Altoona Center for Clinical Research
9:00 AM – 11:00 AM ET
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial Piero Ruscitti, MD, PhD – University of L'Aquila
9:00 AM – 11:00 AM ET
Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis Patryk Drobinski, MSc – University of Copenhagen/Nordic Bioscience
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Iron Management in Patients with Rheumatoid Arthritis Mariusz Chabowski
9:00 AM – 11:00 AM ET
Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History Priyam Das, PhD – Harvard Medical School
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy Yoshinobu Koyama, MD, PhD – Japanese Red Cross Okayama Hospital
9:00 AM – 11:00 AM ET
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK Ernest Choy, MD, FRCP – Cardiff University School of Medicine
9:00 AM – 11:00 AM ET
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors Borja Hernandez-Breijo, PhD – La Paz University Hospital
9:00 AM – 11:00 AM ET
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials Clifton O. Bingham, III, MD – Johns Hopkins University
9:00 AM – 11:00 AM ET
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis Chamaida Plasencia-Rodríguez, Sr, MD, PhD – Hospital Universitario La Paz
9:00 AM – 11:00 AM ET
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis Lilian Otalora Rojas, MD – Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL
9:00 AM – 11:00 AM ET
Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years Vibeke Strand, MD – Stanford University School of Medicine
9:00 AM – 11:00 AM ET
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH) Andrea Rubbert-Roth, MD – Kantonspital St Gallen
9:00 AM – 11:00 AM ET
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA Jonathan Kay, MD – University of Massachusetts Medical School
9:00 AM – 11:00 AM ET
Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab Ernest Choy, MD, FRCP – Cardiff University School of Medicine
9:00 AM – 11:00 AM ET
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND Désirée van der Heijde, MD, PhD – Leiden University Medical Center
9:00 AM – 11:00 AM ET
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials Sebastian Unizony, MD – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials Anthony Sebba, MD – Arthritis Associates
9:00 AM – 11:00 AM ET
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials Gerd R. Burmester, MD – Charité – University Medicine Berlin
9:00 AM – 11:00 AM ET
Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis Peter C. Taylor, MD, PhD, MA – University of Oxford
9:00 AM – 11:00 AM ET
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis Muhammad Shipa, MBBS, MRCP – University College London
